Niki BioSolutions, Inc.

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutics for oncology and infectious diseases. Its pipeline includes SACT-1, a repurposed drug candidate in Phase 1 for neuroblastoma and other cancers; ALS-4, a repurposed small molecule in Phase 1 for bacterial infections such as Staphylococcus aureus, Mycobacterium tuberculosis, and Pseudomonas aeruginosa; and SACT-COV19, a repurposed small molecule in preclinical development for coronavirus disease. The company also develops SACT-2, SACT-3, ALS-1 (preclinical for Staphylococcus aureus infections, including MRSA), and ALS-2/3 (preclinical for gram-positive bacterial infections). Formerly known as Aptorum Group Limited, it changed its name to Niki BioSolutions, Inc. in July 2026. Incorporated in 2010, it is headquartered in Princeton, New Jersey, and operates as a subsidiary of Jurchen Investment Corporation.